Latest filing published 09 Mar 2023 for Aziyo Biologics, INC..
Filing timeline
BuySaleInsider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Thomas Englese: trading record in brief
This profile gathers the share dealings of Thomas Englese in Elutia Inc., where the filings describe the role as senior executive. The record holds 6 filings, for trades running from 14 December 2021 to 9 March 2023.
Both buying and selling appear: 1 purchase worth €25k, against 2 sales worth €1,178. The amount is not disclosed for 1 filing. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Besides market trades, the filings include 3 option exercises. Since January 2023: no purchases and 1 sale on the market.
Most recently, on 9 March 2023, the filings show an open-market sale worth €1,178 in Elutia Inc. The latest purchase dates back some time: it was published 1,791 days ago, on 15 December 2021. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Thomas Englese
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 937 shares0Class A Common StockSEC:0001415889-23-004626:0
- 15,390 sharesClass A Common StockSEC:0001415889-22-009538:0
- 938 shares0Class A Common StockSEC:0001415889-22-002868:0
- 4,580 shares@ US$6.10100.0% of flowClass A Common StockSEC:0001415889-21-005960:0Canonical exit: 14 Mar 2022 (T+90)
4 of 4 declarations
